InsidersTradesSigma
Terns Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)
SEC:terns-pharmaceuticals-inc-31c12eUS·SEC (Form 4)Mcap 777.4Bn€Technology
Discover the full directors' dealings record of Terns Pharmaceuticals, Inc., a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Technology sector, Terns Pharmaceuticals, Inc. has logged 3 public disclosures. Market capitalisation: €777.4bn. The latest transaction was disclosed on 8 June 2022 — Acquisition. Among the most active insiders: Yoon Seokho Bryan. All data is openly available.
3
Insider Decl.
0
Thresholds
€31,454
3 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended August 2025 · cache
689.45 €
Analyst consensus
41 analystsStrong buy
249.00 €Target 584.24 €(-15%)1000.00 €
Income statement
Revenue37.38 Bn€
Gross profit14.87 Bn€40% margin
Net income8.54 Bn€41.5% margin
Valuation
PER (trailing)32.6x
PER (forward)6.7x
P/Book10.7x
Beta1.92
Balance sheet & cash
Market cap777.43 Bn€
Total debt15.28 Bn€
Free Cash Flow1.67 Bn€
Debt / Equity15%
Profitability & ownership
ROE39.8%
ROA20.1%
% insiders0.3%
% institutions81.1%
Last declaration on 8 June 2022
Declarations3 total
Executives▲Purchase44SEC
€10,4857,656 shares@ €1.36950.0000% mcap100.0% of flow
Common Stock
SEC:0001562180-22-004952:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 52SEC
€10,4857,656 shares@ €1.36950.0000% mcap100.0% of flow
Common Stock
SEC:0001562180-22-004951:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 55SEC
€10,4857,656 shares@ €1.36950.0000% mcap100.0% of flow
Common Stock
SEC:0001562180-22-004950:0·
Ideal exit: 25 Feb 2023 (T+270)
3 of 3 declarations